European Consortium Awarded Millions to Develop Therapies for IBD, 2 Other Inflammatory Diseases

European Consortium Awarded Millions to Develop Therapies for IBD, 2 Other Inflammatory Diseases
A new European project coordinated by Kiel University in Germany has been awarded with €14.4 million euros (about $15.3 million U.S. dollars) to develop a personalized medicine approach for predicting and treating three chronic inflammatory diseases: Inflammatory bowel disease (IBD), systemic lupus erythematodes (SLE) and rheumatoid arthritis (RA). The project, “A systems medicine approach to chronic inflammatory disease” (SYSCID), was announced by the European Commission in a recent press release. The project will join academic and industry partners from nine European countries that will actively work toward discovering new ways to predict and treat these conditions, which have distinct characteristics, but overlap significantly in their molecular risk map. Chronic inflammatory diseases have a lifetime prevalence of more than 10% in Europe, and represent a major public health burden. Many genetic and non-genetic factors play a role in chronic inflammatory diseases, and a tailored therapeutic approach could help deliver more effective and timely therapies for those living with these diseases. The consortium will work to identify both shared and unique characteristics, or “core disease signatures,” and build predictive models for disease outcomes. Researchers hope to identify biomarkers that can guide therapeutic decisions on an individual basis. “Our vision is to develop a prediction framework for disease outcome and choice of treatment strategies. With many new targeted therapies coming to the market, we need the right therapy at the right time,” said Philip Rosenstiel, PhD, of the Institute of Clinical Molecula
Subscribe or to access all post and page content.